New drug duo aims to tackle tough lymphoma in immunocompromised patients

NCT ID NCT06723457

Recruiting now Disease control Sponsor: Reem Karmali Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This phase II trial tests whether combining epcoritamab (an immunotherapy that directs immune cells to kill lymphoma) with lenalidomide (which boosts the immune system) can shrink tumors in 34 patients whose immunodeficiency-related large B-cell lymphoma has not responded to treatment or has returned. The main goal is to see how many patients achieve a complete response within six months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Epcoritamab and lenalidomide
What this could lead to: If successful, this combination could offer a new treatment option for patients with hard-to-treat immunodeficiency-related lymphoma who cannot tolerate chemotherapy.
What could go wrong: This is a small, early-phase trial with only 34 participants, so results may not apply broadly. The combination may cause side effects or fail to improve response rates over existing therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma post-transplant lymphoproliferative disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT B-CELL NON-HODGKIN LYMPHOMA RECURRENT POLYMORPHIC POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Northwestern University
RECRUITING

Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.